Catalyst
Slingshot members are tracking this event:
Target Enrollment for Nusinersen Phase 3 Study, CHERISH, in Children with Spinal Muscular Atrophy Completed, as Ionis earns $2.15M Milestone Payment from Biogen
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 12, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Complete Enrollment, Nusinersen, Phase 3, Spinal Muscular Atrophy, Milestone Payment, Sma, Cherish
